Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Drug-delivery system for cervical cancer lesions licensed to CytoCore
March 23rd, 2006
CytoCore, Inc. (MCDG.OB) announced that it has licensed from University Hospitals of Cleveland (Ohio) a new drug-delivery system (DDS) developed by physician George Gorodeski, MD, PhD, that will give the physicians the ability to apply U.S. Food & Drug Administration (FDA)-approved drugs to existing cervical lesions. The DDS is comprised of an applicator handle and drug-delivery modality in the form of a patch that provides a timed-release delivery of the therapeutic agent directly to the surface of the cervix. The handle is a further development of CytoCore's e2 Collector handle, which has been specifically designed to, according to the company, quickly, safely, and...
Source: Women's Health Weekly (2006-03-23)
|
